<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00952276</url>
  </required_header>
  <id_info>
    <org_study_id>FUF16</org_study_id>
    <secondary_id>UTN: U1111-1111-4882</secondary_id>
    <nct_id>NCT00952276</nct_id>
  </id_info>
  <brief_title>A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly</brief_title>
  <official_title>Immunogenicity and Safety of Multiple Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adult and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic
      vaccine in adults and the elderly.

      Primary Objectives:

        -  To describe the immunogenicity of the candidate vaccines after a single injection.

        -  To describe the safety of the candidate vaccines after a single injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will receive a single injection of their randomized vaccine on Day 0.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Detectable Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18 to 64 Years</measure>
    <time_frame>Day 0 and Day 21 post-vaccination</time_frame>
    <description>Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay. Detectable anti HA antibody titer was defined as titers ≥ 10 (1/dilution) on Day 0 and Day 21 post-vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Seroprotection Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18 to 64 Years</measure>
    <time_frame>Day 0 and Day 21 post-vaccination</time_frame>
    <description>Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay. Seroprotection was defined as a titer ≥ 40 (1/dil).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of A/H1N1 Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18 to 64 Years</measure>
    <time_frame>Day 0 and Day 21 post-vaccination</time_frame>
    <description>Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Detectable Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age ≥ 65 Years</measure>
    <time_frame>Day 0 and Day 21 post-vaccination</time_frame>
    <description>Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay. Detectable anti-HA antibody titer was defined as titers ≥ 10 (1/dil).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Seroprotection Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age ≥ 65 Years</measure>
    <time_frame>Day 0 and Day 21 post-vaccination</time_frame>
    <description>Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay. Seroprotection was defined as a titer ≥ 40 (1/dil).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of A/H1N1 Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age ≥ 65 Years</measure>
    <time_frame>Day 0 and Day 21 post-vaccination</time_frame>
    <description>Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting a Solicited Injection Site or Systemic Reaction Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18 to 64 Years</measure>
    <time_frame>Day 0 up to Day 7 post-vaccination</time_frame>
    <description>Solicited Injections Site Reactions: Pain, Erythema, Swelling, Induration, and Ecchymosis. Solicited Systemic Reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting a Solicited Injection Site or Systemic Reaction Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age ≥ 65 Years</measure>
    <time_frame>Day 0 up to Day 7 post-vaccination</time_frame>
    <description>Solicited Injections Site Reactions: Pain, Erythema, Swelling, Induration, and Ecchymosis. Solicited Systemic Reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">548</enrollment>
  <condition>Influenza</condition>
  <condition>Swine-origin A/H1N1 Influenza</condition>
  <arm_group>
    <arm_group_label>A/H1N1 Vaccine Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive A/H1N1 vaccine formulation 1 (with adjuvant)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/H1N1 Vaccine Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive A/H1N1 vaccine formulation 2 (with adjuvant)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/H1N1 Vaccine Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive A/H1N1 vaccine formulation 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/H1N1 Vaccine Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive A/H1N1 vaccine formulation 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a placebo vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant</intervention_name>
    <description>0.5 mL, Intramuscular on Day 0</description>
    <arm_group_label>A/H1N1 Vaccine Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant</intervention_name>
    <description>0.5 mL, Intramuscular on Day 0</description>
    <arm_group_label>A/H1N1 Vaccine Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent Subvirion A/H1N1 influenza vaccine</intervention_name>
    <description>0.5 mL, Intramuscular on Day 0</description>
    <arm_group_label>A/H1N1 Vaccine Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent Subvirion A/H1N1 influenza vaccine</intervention_name>
    <description>0.5 mL, Intramuscular on Day 0</description>
    <arm_group_label>A/H1N1 Vaccine Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Normal saline solution</intervention_name>
    <description>0.5 mL, Intramuscular on Day 0</description>
    <arm_group_label>Placebo Group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Healthy adults aged 18 years or older on the day of inclusion

          -  Informed consent has been signed and dated

          -  Able to attend all scheduled visits and comply with all trial procedures

          -  For a woman of child-bearing potential, use of an effective method of contraception or
             abstinence from at least 4 weeks prior to the first vaccination, until at least 4
             weeks after last vaccination.

        Exclusion Criteria :

          -  Known pregnancy or positive urine pregnancy test

          -  Currently breastfeeding a child

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or a medical procedure in the 4 weeks preceding the first trial vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Receipt of any vaccine in the 4 weeks preceding the trial vaccination, except for the
             inactivated seasonal influenza vaccine, within two weeks preceding trial vaccination

          -  Planned receipt of any vaccine prior to the Day 42 blood sample

          -  Receipt of blood or blood-derived products in the past 3 months which might interfere
             with the assessment of immune response

          -  Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy
             such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months,
             or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2
             consecutive weeks within the past 3 months)

          -  Self-reported seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B
             antigen, or Hepatitis C

          -  Known systemic hypersensitivity to any of the vaccine components, or history of a
             life-threatening reaction to the vaccine(s) used in the trial or to a vaccine
             containing any of the same substances

          -  Self reported thrombocytopenia contraindicating intramuscular (IM) vaccination

          -  Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion
             contraindicating IM vaccination

          -  Deprived of freedom by an administrative or court order, or in an emergency setting,
             or hospitalized involuntarily

          -  Current alcohol abuse or drug addiction that may interfere with the subject's ability
             to comply with trial procedures

          -  Chronic illness that in the opinion of the Investigator, is at a stage where it might
             interfere with trial conduct or completion

          -  Employees of the Investigator or study center, with direct involvement in the proposed
             study or other studies under the direction of that Investigator or study center, as
             well as family members of the employees or the Investigator

          -  Previous participation in a swine-origin A/H1N1 pandemic flu trial except if performed
             in 1976

          -  Any confirmed case of influenza (including swine-origin A/H1N1 Influenza) since March
             2009

          -  Febrile illness (temperature ≥ 100.4°F [≥ 38.0°C ]) or moderate or severe acute
             illness/infection (according to Investigator judgment) on the day of vaccination

          -  Personal or family history of Guillain-Barré syndrome

          -  Active neoplastic disease or a history of any hematologic malignancy

          -  Known seizure/epilepsy history and/or taking anti-seizure medication

          -  Receipt of psychiatric drugs. Subjects receiving a single antidepressant drug and
             stable for at least 3 months prior to enrollment, without decompensating symptoms will
             be allowed to enroll in the study

          -  Any Grade 1, 2, or 3 liver function values (Alanine aminotransferase (ALT), Aspartate
             aminotransferase (AST), and Alkaline phosphatase) observed in blood sample taken at
             Screening

          -  Any Grade 2 or Grade 3 laboratory abnormalities in blood sample taken at Screening

          -  Receipt of any monovalent 2009 pandemic H1N1 vaccine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grove City</city>
        <state>Pennsylvania</state>
        <zip>16127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jefferson Hills</city>
        <state>Pennsylvania</state>
        <zip>15025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springville</city>
        <state>Utah</state>
        <zip>84663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofiaventis.com</url>
  </link>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2009</study_first_submitted>
  <study_first_submitted_qc>August 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <results_first_submitted>August 26, 2011</results_first_submitted>
  <results_first_submitted_qc>August 26, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 3, 2011</results_first_posted>
  <last_update_submitted>August 26, 2011</last_update_submitted>
  <last_update_submitted_qc>August 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza Pandemic Flu Swine-origin A/H1N1 Influenza Adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 29 October 2009 to 13 November 2009 at 14 US clinical centers.</recruitment_details>
      <pre_assignment_details>A total of 548 participants who met the inclusion and exclusion criteria were enrolled, vaccinated, and included in data analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: A/H1N1 Vaccine Formulation 1 + Adjuvant</title>
          <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) with adjuvant on Day 0</description>
        </group>
        <group group_id="P2">
          <title>Group 2: A/H1N1 Vaccine Formulation 2 + Adjuvant</title>
          <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) with adjuvant on Day 0</description>
        </group>
        <group group_id="P3">
          <title>Group 3: A/H1N1 Vaccine Formulation 3</title>
          <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) on Day 0</description>
        </group>
        <group group_id="P4">
          <title>Group 4: A/H1N1 Vaccine Formulation 4</title>
          <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) on Day 0</description>
        </group>
        <group group_id="P5">
          <title>Group 5: Placebo</title>
          <description>Participants who received a dose of placebo (normal saline) on Day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="122"/>
                <participants group_id="P4" count="121"/>
                <participants group_id="P5" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="122"/>
                <participants group_id="P4" count="120"/>
                <participants group_id="P5" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: A/H1N1 Vaccine Formulation 1 + Adjuvant</title>
          <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) with adjuvant on Day 0</description>
        </group>
        <group group_id="B2">
          <title>Group 2: A/H1N1 Vaccine Formulation 2 + Adjuvant</title>
          <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) with adjuvant on Day 0</description>
        </group>
        <group group_id="B3">
          <title>Group 3: A/H1N1 Vaccine Formulation 3</title>
          <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) on Day 0</description>
        </group>
        <group group_id="B4">
          <title>Group 4: A/H1N1 Vaccine Formulation 4</title>
          <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) on Day 0</description>
        </group>
        <group group_id="B5">
          <title>Group 5: Placebo</title>
          <description>Participants who received a dose of placebo (normal saline) on Day 0</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="127"/>
            <count group_id="B2" value="115"/>
            <count group_id="B3" value="122"/>
            <count group_id="B4" value="121"/>
            <count group_id="B5" value="63"/>
            <count group_id="B6" value="548"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="71"/>
                    <measurement group_id="B5" value="38"/>
                    <measurement group_id="B6" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age Continuous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.0" spread="18.4"/>
                    <measurement group_id="B2" value="53.3" spread="18.7"/>
                    <measurement group_id="B3" value="51.9" spread="18.0"/>
                    <measurement group_id="B4" value="52.7" spread="19.9"/>
                    <measurement group_id="B5" value="54.7" spread="16.7"/>
                    <measurement group_id="B6" value="53.4" spread="18.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="121"/>
                    <measurement group_id="B5" value="63"/>
                    <measurement group_id="B6" value="548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Detectable Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18 to 64 Years</title>
        <description>Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay. Detectable anti HA antibody titer was defined as titers ≥ 10 (1/dilution) on Day 0 and Day 21 post-vaccination.</description>
        <time_frame>Day 0 and Day 21 post-vaccination</time_frame>
        <population>Pre and post-vaccination antibody titers were assessed in the per-protocol population aged 18 to 64 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: A/H1N1 Vaccine Formulation 1 + Adjuvant</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) with adjuvant on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Group 2: A/H1N1 Vaccine Formulation 2 + Adjuvant</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) with adjuvant on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Group 3: A/H1N1 Vaccine Formulation 3</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Group 4: A/H1N1 Vaccine Formulation 4</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Placebo</title>
            <description>Participants who received a dose of placebo (normal saline) on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Detectable Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18 to 64 Years</title>
          <description>Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay. Detectable anti HA antibody titer was defined as titers ≥ 10 (1/dilution) on Day 0 and Day 21 post-vaccination.</description>
          <population>Pre and post-vaccination antibody titers were assessed in the per-protocol population aged 18 to 64 years.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (Pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 (Post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="68"/>
                    <measurement group_id="O5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Seroprotection Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18 to 64 Years</title>
        <description>Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay. Seroprotection was defined as a titer ≥ 40 (1/dil).</description>
        <time_frame>Day 0 and Day 21 post-vaccination</time_frame>
        <population>Pre and post-vaccination antibody titers were assessed in the per-protocol population aged 18 to 64 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: A/H1N1 Vaccine Formulation 1 + Adjuvant</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) with adjuvant on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Group 2: A/H1N1 Vaccine Formulation 2 + Adjuvant</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) with adjuvant on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Group 3: A/H1N1 Vaccine Formulation 3</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Group 4: A/H1N1 Vaccine Formulation 4</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Placebo</title>
            <description>Participants who received a dose of placebo (normal saline) on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seroprotection Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18 to 64 Years</title>
          <description>Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay. Seroprotection was defined as a titer ≥ 40 (1/dil).</description>
          <population>Pre and post-vaccination antibody titers were assessed in the per-protocol population aged 18 to 64 years.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (Pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 (Post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="64"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) of A/H1N1 Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18 to 64 Years</title>
        <description>Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay.</description>
        <time_frame>Day 0 and Day 21 post-vaccination</time_frame>
        <population>Pre and post-vaccination antibody titers were assessed in the per-protocol population aged 18 to 64 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: A/H1N1 Vaccine Formulation 1 + Adjuvant</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) with adjuvant on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Group 2: A/H1N1 Vaccine Formulation 2 + Adjuvant</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) with adjuvant on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Group 3: A/H1N1 Vaccine Formulation 3</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Group 4: A/H1N1 Vaccine Formulation 4</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Placebo</title>
            <description>Participants who received a dose of placebo (normal saline) on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of A/H1N1 Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18 to 64 Years</title>
          <description>Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay.</description>
          <population>Pre and post-vaccination antibody titers were assessed in the per-protocol population aged 18 to 64 years.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (Pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" lower_limit="16.2" upper_limit="34.6"/>
                    <measurement group_id="O2" value="21.0" lower_limit="14.4" upper_limit="30.5"/>
                    <measurement group_id="O3" value="23.8" lower_limit="17.1" upper_limit="33.1"/>
                    <measurement group_id="O4" value="27.7" lower_limit="18.4" upper_limit="41.7"/>
                    <measurement group_id="O5" value="20.0" lower_limit="11.2" upper_limit="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 (Post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="896" lower_limit="673" upper_limit="1195"/>
                    <measurement group_id="O2" value="900" lower_limit="653" upper_limit="1241"/>
                    <measurement group_id="O3" value="470" lower_limit="314" upper_limit="705"/>
                    <measurement group_id="O4" value="608" lower_limit="423" upper_limit="875"/>
                    <measurement group_id="O5" value="26.3" lower_limit="15.0" upper_limit="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Detectable Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age ≥ 65 Years</title>
        <description>Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay. Detectable anti-HA antibody titer was defined as titers ≥ 10 (1/dil).</description>
        <time_frame>Day 0 and Day 21 post-vaccination</time_frame>
        <population>Pre and post-vaccination antibody titers were assessed in the per-protocol population aged 65 years or older.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: A/H1N1 Vaccine Formulation 1 + Adjuvant</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) with adjuvant on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Group 2: A/H1N1 Vaccine Formulation 2 + Adjuvant</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) with adjuvant on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Group 3: A/H1N1 Vaccine Formulation 3</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Group 4: A/H1N1 Vaccine Formulation 4</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Placebo</title>
            <description>Participants who received a dose of placebo (normal saline) on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Detectable Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age ≥ 65 Years</title>
          <description>Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay. Detectable anti-HA antibody titer was defined as titers ≥ 10 (1/dil).</description>
          <population>Pre and post-vaccination antibody titers were assessed in the per-protocol population aged 65 years or older.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (Pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 (Post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Seroprotection Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age ≥ 65 Years</title>
        <description>Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay. Seroprotection was defined as a titer ≥ 40 (1/dil).</description>
        <time_frame>Day 0 and Day 21 post-vaccination</time_frame>
        <population>Pre and post-vaccination antibody titers were assessed in the per-protocol population aged 65 years or older.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: A/H1N1 Vaccine Formulation 1 + Adjuvant</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) with adjuvant on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Group 2: A/H1N1 Vaccine Formulation 2 + Adjuvant</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) with adjuvant on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Group 3: A/H1N1 Vaccine Formulation 3</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Group 4: A/H1N1 Vaccine Formulation 4</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Placebo</title>
            <description>Participants who received a dose of placebo (normal saline) on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seroprotection Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age ≥ 65 Years</title>
          <description>Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay. Seroprotection was defined as a titer ≥ 40 (1/dil).</description>
          <population>Pre and post-vaccination antibody titers were assessed in the per-protocol population aged 65 years or older.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (Pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 (Post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) of A/H1N1 Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age ≥ 65 Years</title>
        <description>Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay.</description>
        <time_frame>Day 0 and Day 21 post-vaccination</time_frame>
        <population>Pre and post-vaccination antibody titers were assessed in the per-protocol population aged 65 years or older.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: A/H1N1 Vaccine Formulation 1 + Adjuvant</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) with adjuvant on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Group 2: A/H1N1 Vaccine Formulation 2 + Adjuvant</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) with adjuvant on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Group 3: A/H1N1 Vaccine Formulation 3</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Group 4: A/H1N1 Vaccine Formulation 4</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Placebo</title>
            <description>Participants who received a dose of placebo (normal saline) on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of A/H1N1 Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age ≥ 65 Years</title>
          <description>Antibodies to vaccine were measured using the Hemagglutinin Inhibition (HAI) assay.</description>
          <population>Pre and post-vaccination antibody titers were assessed in the per-protocol population aged 65 years or older.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (Pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" lower_limit="18.3" upper_limit="44.3"/>
                    <measurement group_id="O2" value="40.0" lower_limit="25.7" upper_limit="62.2"/>
                    <measurement group_id="O3" value="26.1" lower_limit="18.3" upper_limit="37.2"/>
                    <measurement group_id="O4" value="23.0" lower_limit="16.4" upper_limit="32.1"/>
                    <measurement group_id="O5" value="25.7" lower_limit="14.6" upper_limit="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 (Post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="501" lower_limit="330" upper_limit="761"/>
                    <measurement group_id="O2" value="630" lower_limit="432" upper_limit="920"/>
                    <measurement group_id="O3" value="177" lower_limit="108" upper_limit="292"/>
                    <measurement group_id="O4" value="189" lower_limit="118" upper_limit="301"/>
                    <measurement group_id="O5" value="26.8" lower_limit="14.7" upper_limit="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting a Solicited Injection Site or Systemic Reaction Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18 to 64 Years</title>
        <description>Solicited Injections Site Reactions: Pain, Erythema, Swelling, Induration, and Ecchymosis. Solicited Systemic Reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering</description>
        <time_frame>Day 0 up to Day 7 post-vaccination</time_frame>
        <population>Safety analysis was on all enrolled and vaccinated participants with available reaction data, intent to treat population aged 18 to 64 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: A/H1N1 Vaccine Formulation 1 + Adjuvant</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) with adjuvant on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Group 2: A/H1N1 Vaccine Formulation 2 + Adjuvant</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) with adjuvant on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Group 3: A/H1N1 Vaccine Formulation 3</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Group 4: A/H1N1 Vaccine Formulation 4</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Placebo</title>
            <description>Participants who received a dose of placebo (normal saline) on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting a Solicited Injection Site or Systemic Reaction Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18 to 64 Years</title>
          <description>Solicited Injections Site Reactions: Pain, Erythema, Swelling, Induration, and Ecchymosis. Solicited Systemic Reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering</description>
          <population>Safety analysis was on all enrolled and vaccinated participants with available reaction data, intent to treat population aged 18 to 64 years.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Solicited Injection Site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain (Prevents daily activity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Injection Site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema (&gt; 10 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Injection Site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (&gt; 10 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Injection Site Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Induration (&gt; 10 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Injection Site Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (≥ 102.1 ºF or ≥ 39.0 ºC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (Prevents daily activity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (Prevents daily activity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (Prevents daily activity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering (Prevents daily activity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting a Solicited Injection Site or Systemic Reaction Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age ≥ 65 Years</title>
        <description>Solicited Injections Site Reactions: Pain, Erythema, Swelling, Induration, and Ecchymosis. Solicited Systemic Reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering.</description>
        <time_frame>Day 0 up to Day 7 post-vaccination</time_frame>
        <population>Safety analysis was on all enrolled and vaccinated participants with available reaction data, intent-to-treat population aged 65 years or older.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: A/H1N1 Vaccine Formulation 1 + Adjuvant</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) with adjuvant on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Group 2: A/H1N1 Vaccine Formulation 2 + Adjuvant</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) with adjuvant on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Group 3: A/H1N1 Vaccine Formulation 3</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Group 4: A/H1N1 Vaccine Formulation 4</title>
            <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Placebo</title>
            <description>Participants who received a dose of placebo (normal saline) on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting a Solicited Injection Site or Systemic Reaction Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age ≥ 65 Years</title>
          <description>Solicited Injections Site Reactions: Pain, Erythema, Swelling, Induration, and Ecchymosis. Solicited Systemic Reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering.</description>
          <population>Safety analysis was on all enrolled and vaccinated participants with available reaction data, intent-to-treat population aged 65 years or older.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Solicited Injection Site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain (Prevents daily activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Injection Site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema (&gt; 10 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Injection Site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (&gt; 10 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Injection Site Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Induration (&gt; 10 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Injection Site Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Ecchymosis (&gt; 10 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (≥ 102.1 ºF or ≥ 39.0 ºC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (Prevents daily activity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (Prevents daily activity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (Prevents daily activity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering (Prevents daily activity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the day of vaccination (Day 0) up to 12 months post-vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1: A/H1N1 Vaccine Formulation 1 + Adjuvant</title>
          <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) with adjuvant on Day 0</description>
        </group>
        <group group_id="E2">
          <title>Group 2: A/H1N1 Vaccine Formulation 2 + Adjuvant</title>
          <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) with adjuvant on Day 0</description>
        </group>
        <group group_id="E3">
          <title>Group 3: A/H1N1 Vaccine Formulation 3</title>
          <description>Participants who received a dose of A/H1N1 vaccine containing 3.8 µg hemagglutinin (HA) on Day 0</description>
        </group>
        <group group_id="E4">
          <title>Group 4: A/H1N1 Vaccine Formulation 4</title>
          <description>Participants who received a dose of A/H1N1 vaccine containing 7.5 µg hemagglutinin (HA) on Day 0</description>
        </group>
        <group group_id="E5">
          <title>Group 5: Placebo</title>
          <description>Participants who received a dose of placebo (normal saline) on Day 0</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="82" subjects_at_risk="121"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="73" subjects_affected="73" subjects_at_risk="127"/>
                <counts group_id="E2" events="75" subjects_affected="75" subjects_at_risk="115"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="122"/>
                <counts group_id="E4" events="24" subjects_affected="24" subjects_at_risk="121"/>
                <counts group_id="E5" events="13" subjects_affected="13" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="127"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="115"/>
                <counts group_id="E3" events="23" subjects_affected="23" subjects_at_risk="122"/>
                <counts group_id="E4" events="17" subjects_affected="17" subjects_at_risk="121"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="122"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="121"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="90" subjects_affected="77" subjects_at_risk="127"/>
                <counts group_id="E2" events="78" subjects_affected="70" subjects_at_risk="115"/>
                <counts group_id="E3" events="77" subjects_affected="69" subjects_at_risk="122"/>
                <counts group_id="E4" events="91" subjects_affected="81" subjects_at_risk="121"/>
                <counts group_id="E5" events="42" subjects_affected="37" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="122"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="121"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="48" subjects_at_risk="127"/>
                <counts group_id="E2" events="39" subjects_affected="39" subjects_at_risk="115"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="121"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="121"/>
                <counts group_id="E5" events="14" subjects_affected="14" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="127"/>
                <counts group_id="E2" events="37" subjects_affected="37" subjects_at_risk="115"/>
                <counts group_id="E3" events="30" subjects_affected="30" subjects_at_risk="122"/>
                <counts group_id="E4" events="34" subjects_affected="34" subjects_at_risk="121"/>
                <counts group_id="E5" events="18" subjects_affected="18" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E3" events="12" subjects_affected="6" subjects_at_risk="122"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

